Sun, Jan 25, 2015, 10:23 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Dec. 2 - 3rd followed by ISI Medtools &outsourcing Investor forum Dec. 3rd - 4th. Then in Jan we are at the 33rd annual JP Morgan Healthcare Conference. Lots of big players at these conferences. Good exposure.

    Sentiment: Strong Buy

  • this_isnt_my_real_alias this_isnt_my_real_alias Nov 20, 2014 12:58 PM Flag

    Yes.......sheep.

  • So, people who sold yesterday are the ones who follow Zack's recommendations and the ones who follow the ones who follow Zack.

    Sentiment: Strong Buy

  • Reply to

    Volatile PACB

    by stocktrader2020 Nov 14, 2014 2:36 PM

    all we need is profit.

    Sentiment: Strong Buy

  • this_isnt_my_real_alias this_isnt_my_real_alias Nov 20, 2014 11:55 AM Flag

    Haha... They(Zacks) really don't need to know what's going on behind closed doors.......all they have to do is follow the positive news, just like we are doing.

  • They don't actually follow the companies progress or where they are in manufacturing their products or pipeline. All they do is follow the charts and other indicators, then plug this info into their computers. They have no idea what's going on behind closed doors.

    Sentiment: Strong Buy

  • In October the blog site (Zacks) put an Outperform rating on PACB, yesterday the put a neutral on PACB with a price target of $7.30.

    Kind of ridiculous to initiate an Outperform in October, then in November go Neutral on the stock, especially in light of the positive news releases since then.

    They claim to have a stellar track record, but I myself have followed some of their stock picks in the past, never bought any of them, but just wanted to see how great they were/are, some of the junk they pick as Buys I wouldn't touch with a ten foot pole. The ones they do "pick" that are worthwhile are the obvious ones that most already know about.

    They have about the same influence on stock price as SA writers, in my opinion.

    Yeah, Outperform in October, Neutral in November?

    I guess the better the news gets, the more Neutral they are on the stock ?

    Look at their opinion on PACB on October 22, it's on the main page for PACB here on Yahoo.

  • Reply to

    Volatile PACB

    by stocktrader2020 Nov 14, 2014 2:36 PM

    Programmed trading yesterday. Nearly all in the red especially the ones with recent spikes. This is the normal anymore. No worries here though. Great company, great product, big partner, working on new equipment, constantly upgrading, insiders buying big, milestone payments coming, well funded, what more do you want. Will be right back up soon. GLTAL's.

    Sentiment: Strong Buy

  • Reply to

    Volatile PACB

    by stocktrader2020 Nov 14, 2014 2:36 PM

    PACB told you so, this is going down!!

    Sentiment: Strong Sell

  • Thanks for sharing these news items!

  • SciLifeLabs just approved the first 21 National Projects focused on human whole genome sequencing and biodiversity. Four projects by researchers from Stockholm University were approved. In total, thousands of genomes will be sequenced within the projects.

    Johanna Cannon with “New methods for ancient worms: applying low-input protocols for single-molecule real-time (SMRT) sequencing to Acoelomorpha”

    Johanna Cannon, Postdoctoral Researcher at the Swedish Museum of Natural History, is one of the scientists whose project has been granted. Her research deals with tiny marine animals called acoels that are at the crux of a number of important transitions in evolutionary history.

    − These animals cannot be grown in culture, and have large genomes that have proven difficult to sequence with traditional approaches. With this SciLifeLab funding, we can employ cutting-edge DNA sequencing technologies to generate complete genomes of these animals and to elucidate genomic signatures that underlie key evolutionary innovations in animal diversity. Success of this project will provide answers to a number of major evolutionary questions, and will help develop innovative third-generation sequencing approaches for small organisms with large genomes, said Johanna Cannon.

    "Going where no other sequencer has been before"

    Sentiment: Buy

  • Reply to

    United Kingdom Invests in SMRT Technology!

    by investments2bn Nov 18, 2014 6:28 PM

    It just keeps getting better, simple as that.

  • November 15, 2014

    The University of Exeter Medical School has been awarded £1.6 million from the Medical Research Council (MRC) to fund a state-of-the-art facility that will unlock some of the hidden secrets of the genome. The announcement was made by Vince Cable, Secretary of State for Business, Innovation and Skills.

    The award, made as part of the MRC’s Clinical Research Infrastructure initiative, will enable Exeter researchers to invest in single molecule real-time (SMRT) sequencing technology and also expand their high performance computing facilities for the analysis of complex genomic data.

    The new technology will enable researchers to identify and analyse regions of the genome hidden from current methods for gene discovery, facilitating research into the functional mechanisms involved in disease. Only three other SMRT sequencers are currently installed in the UK, and this will be the first directly embedded within a clinical research facility.

    Professor Jonathan Mill, of the University of Exeter Medical School, who led the bid for the award, said: “The last decade has seen tremendous advances in understanding about the role of genetic variation in health and disease. Despite this success, however, many regions of the genome remain hidden to contemporary DNA sequencing approaches.

    “Our group at Exeter will acquire "third generation" DNA sequencing technology, which will enable us to fully characterise genomic complexity. We will also establish high-performance computing infrastructure needed to store and analyse this complex data.

    “This important investment will enable us to make significant advances in genomics research in areas including diabetes, neurological and other medical conditions by defining genetic variation in regions where DNA does not encode proteins.”

    Sentiment: Buy

  • Reply to

    Something within happening soon?

    by j.mo Nov 13, 2014 1:19 PM

    Since you #$%$re so well informed, ple#$%$se enlighten us with your wisdom on p#$%$cbio technology #$%$nd where it is going.

    And you outright s#$%$id "something going to h#$%$ppen by end of ye#$%$r". You're nothing but #$%$ pumper who is here trying to suggest something #$%$nd m#$%$nipul#$%$te people to move the stock...try posting something me#$%$ningful inste#$%$d of insults #$%$nd empty posts th#$%$t w#$%$ste peoples time.

  • Reply to

    Something within happening soon?

    by j.mo Nov 13, 2014 1:19 PM
    j.mo@sbcglobal.net j.mo Nov 18, 2014 9:40 AM Flag

    I said "maybe" in my post...it was speculative and I was inquiring whether anyone had any insight. You're the total moron....anyone that thinks comments in chat board actually a sway stock like this one is a complete idiot. Also, don't preach to me about this technology and where they need to go; I know already.

  • Reply to

    Something within happening soon?

    by j.mo Nov 13, 2014 1:19 PM

    this kind of statement "maybe employees who hear things" is pointless and based on nothing. You also know nothing about "something going to happen by before year's end".

    I am long this stock but brainless pumping like this detracts from the real Pacbio story, which is that they have a niche technology right now that no one else can fill.

    They have a way to go to start selling more machines. They are expensive and the machines are physically large, but my hope is as more people start to get them that the stigma they have wears off and people start to take a serious look at their advantages and make the leap and buy machines. Then the numbers will be there and no pumping will be needed to drive this stock much higher. I don't know if any of this will happen, but am betting right now that it will.

  • Reply to

    Something within happening soon?

    by j.mo Nov 13, 2014 1:19 PM

    Would be nice, whether any news comes out soon or not, we could be retesting new high soon. Only very light resistance around $7.40 ish, followed by more blue sky. Short - Long term, and everything inbetween reading Very Bullish. GLTAL's.

    Sentiment: Strong Buy

  • Reply to

    Something within happening soon?

    by j.mo Nov 13, 2014 1:19 PM
    j.mo@sbcglobal.net j.mo Nov 17, 2014 1:34 PM Flag

    agreed--sooner rather than later. Something's going to happen before year's end. Low volume buying today maybe employees who hear things. Illumina up big today too, and they just got sued for patent infringement! Illumina to Pay Syntrix $70M to Settle IP Fight (goggle it today).

  • Reply to

    Volatile PACB

    by stocktrader2020 Nov 14, 2014 2:36 PM

    stocktrader2020,

    Bottom line, if you are afraid of the volatility of PACB, then find a stock that's within your comfort level.

    This stock is volatile!

    I can live with this investment because I know that Pacific Biosciences has the best technology when it comes to finding the most obscure parts of the genome that no other instrument on the market can detect.

    Genome research companies all over the world will gladly pay for the Pacbio RSII to have a chance to discover cures to diseases that have been hidden due to inferior technologies.

    Sentiment: Strong Buy

  • Reply to

    Volatile PACB

    by stocktrader2020 Nov 14, 2014 2:36 PM

    We hit $7.00 yesterday, and we are still above $6.63. It really doesn't take much volume to move the needle on this one, that's why when we get any good news this thing will fly.

    Sentiment: Strong Buy

PACB
7.88-0.02(-0.25%)Jan 23 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.